Introduction/ObjectivesMisinformation about the safety, efficacy and legality of compounded Glucagon-like peptide-1 receptor agonists and dual action Glucose-dependent Insulinotropic Polypeptide/Glucagon-like peptide-1 receptor agonists (GLP-1 and dual GIP/GLP-1 RA) exists amongst the public. Literature describing healthcare professionals' current awareness and use of these products is limited. The objective of this study is to examine healthcare clinicians' and pharmacists' knowledge and patient care practices for compounded GLP-1 and dual GIP/GLP-1 RAs.MethodsAn observational, cross-sectional 14-item survey was distributed to clinicians and pharmacists who care for patients prescribed GLP-1 or dual GIP/GLP-1 RA in regular practice located throughout a multi-site health system in December of 2025. Responses were collected through REDCap and analyzed using Wilcoxon Rank-Sum and Chi-Square tests.ResultsOf 523 surveys distributed, ninety-nine eligible responses were analyzed. Fifty-one percent of respondents were aware of the 2024 American Diabetes Association (ADA) guidance statement on compounded GLP-1 and dual GIP/GLP-1 RAs. A majority of respondents expressed low confidence in the safety of these agents and have not incorporated them into practice citing safety, efficacy, legality and knowledge gaps. Many respondents expressed a desire for additional education.ConclusionUse of compounded GLP-1 and dual GIP/GLP-1 receptor agonists continues despite regulatory changes and is likely to persist. Gaps in knowledge, awareness, and confidence regarding safety, efficacy, and regulation may be limiting appropriate use, even as clinicians and pharmacists recognize potential benefits for cost and access. These findings expose the need for targeted, interdisciplinary education and clear guidance on compounding regulations.
